• Twitter
  • Linkedin
  • Youtube
  • Facebook
  • Instagram
  • Email
AbbVie News Center
News Center
  • Facebook
  • Twitter
  • Youtube
  • Linkedin
  • Email
  • Search
  • Home
  • News
    • Press Releases
    • News Briefs
    • Media Statements
  • Press Kits
  • Media Resources
    • Fact Sheets
    • Images
    • Video
  • Media Contacts
  1. Home
  2. News
  3. Media Statements

Media statements

These AbbVie statements and notices detail our position on various topics. Read on to learn our point of view on specific health issues.

AbbVie and the Medicines Patent Pool Complete New Licensing Agreement to Ensure Sustainable Access to Pan-genotypic Hepatitis C Medicine Glecaprevir/Pibrentasvir

AbbVie Statement on Preliminary Dutch Auction Tender Offer Results

HUMIRA® (adalimumab) Formulation Update

AbbVie Statement on SONAR Study Closure

AbbVie Statement on Hurricane Impact

AbbVie Statement on Drug Pricing

AbbVie’s Open Public Hearing Comments at FDA Arthritis Advisory Committee Meeting – July 12, 2016, for ABP 501

AbbVie Completes New Licensing Agreement to Address Growing Demand for HIV Treatments in Africa

AbbVie committed to HIV supply in South Africa

AbbVie Statement Regarding Pharmacy Solutions

  • «
  • 1
  • 2
  • »
  • ← << Back
  • Next >> →

  • Share on social media

  • Subscribe to email alerts

    Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.

    Learn More

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

For more information
Contact us »

Subscribe for email alerts
Sign up
Subscription management

AbbVie social media
twitter facebook linkedin Instagram youtube

We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. Before engaging, please read and adhere to our established community guidelines for each channel.

View our social media channel guidelines »

AbbVie.com | Site map | Privacy policy | Terms of use

Copyright © 2020 AbbVie Inc. North Chicago, Illinois, U.S.A.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?